Literature DB >> 6739728

Mean inactivation dose: a useful concept for intercomparison of human cell survival curves.

B Fertil, H Dertinger, A Courdi, E P Malaise.   

Abstract

The mean inactivation dose (D) is calculated for published in vitro survival curves obtained from cell lines of both normal and neoplastic human tissues. Cells belonging to different histological categories (melanomas, carcinomas, etc.) are shown to be characterized by distinct values of D which are related to the clinical radiosensitivity of tumors from these categories. Compared to other ways of representing in vitro radiosensitivity, e.g., by the multitarget parameters D0 and n, the parameter D has several specific advantages: (i) D is representative for the whole cell population rather than for a fraction of it; (ii) it minimizes the fluctuations of the survival curves of a given cell line investigated by different authors; (iii) there is low variability of D within each histological category; (iv) significant differences in radiosensitivity between the categories emerge when using D. D appears to be a useful concept for specifying intrinsic radiosensitivity of human cell lines.

Entities:  

Mesh:

Year:  1984        PMID: 6739728

Source DB:  PubMed          Journal:  Radiat Res        ISSN: 0033-7587            Impact factor:   2.841


  86 in total

1.  Boron neutron capture enhancement (BNCE) of fast neutron irradiation for glioblastoma: increase of thermal neutron flux with heavy material collimation, a theoretical evaluation.

Authors:  P Paquis; J P Pignol; M Lonjon; N Brassart; A Courdi; P Chauvel; P Grellier; M Chatel
Journal:  J Neurooncol       Date:  1999-01       Impact factor: 4.130

2.  Differential proliferation dependence of alpha and beta damage in X-irradiated Chinese hamster cells.

Authors:  D Bartkowiak; W Nothdurft; E M Röttinger
Journal:  Strahlenther Onkol       Date:  1999-05       Impact factor: 3.621

3.  Studies on the influence of DNA repair on radiosensitivity in prostate cell lines.

Authors:  Antonio M Serafin; John M Akudugu; Lothar Böhm
Journal:  Urol Res       Date:  2003-04-01

4.  GSK3beta and beta-catenin modulate radiation cytotoxicity in pancreatic cancer.

Authors:  Richard L Watson; Aaron C Spalding; Steven P Zielske; Meredith Morgan; Alex C Kim; Guido T Bommer; Hagit Eldar-Finkelman; Thomas Giordano; Eric R Fearon; Gary D Hammer; Theodore S Lawrence; Edgar Ben-Josef
Journal:  Neoplasia       Date:  2010-05       Impact factor: 5.715

5.  HPV16-E7 expression causes fluorodeoxyuridine-mediated radiosensitization in SW620 human colon cancer cells.

Authors:  M D Axelson; M A Davis; S P Ethier; T S Lawrence
Journal:  Neoplasia       Date:  1999-06       Impact factor: 5.715

6.  Radiosensitization of human pancreatic cancer cells by MLN4924, an investigational NEDD8-activating enzyme inhibitor.

Authors:  Dongping Wei; Hua Li; Jie Yu; Jonathan T Sebolt; Lili Zhao; Theodore S Lawrence; Peter G Smith; Meredith A Morgan; Yi Sun
Journal:  Cancer Res       Date:  2011-11-09       Impact factor: 12.701

7.  A Ku80 fragment with dominant negative activity imparts a radiosensitive phenotype to CHO-K1 cells.

Authors:  E Marangoni; N Foray; M O'Driscoll; S Douc-Rasy; J Bernier; J Bourhis; P Jeggo
Journal:  Nucleic Acids Res       Date:  2000-12-01       Impact factor: 16.971

8.  CD44 is a biomarker associated with human prostate cancer radiation sensitivity.

Authors:  WeiWei Xiao; Peter H Graham; Carl A Power; Jingli Hao; John H Kearsley; Yong Li
Journal:  Clin Exp Metastasis       Date:  2011-09-28       Impact factor: 5.150

9.  Criteria and techniques for analysing cell survival data.

Authors:  D Bettega; P Calzolari; A Ottolenghi; L Tallone Lombardi
Journal:  Radiat Environ Biophys       Date:  1991       Impact factor: 1.925

10.  Radiation-induced acid ceramidase confers prostate cancer resistance and tumor relapse.

Authors:  Joseph C Cheng; Aiping Bai; Thomas H Beckham; S Tucker Marrison; Caroline L Yount; Katherine Young; Ping Lu; Anne M Bartlett; Bill X Wu; Barry J Keane; Kent E Armeson; David T Marshall; Thomas E Keane; Michael T Smith; E Ellen Jones; Richard R Drake; Alicja Bielawska; James S Norris; Xiang Liu
Journal:  J Clin Invest       Date:  2013-09-16       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.